Life science company ValiRx Plc (AIM: VAL), announced on Monday that it has concluded its Evaluation project with Imperial College London, previously announced on 21 March 2024.

Following the collaboration agreement, the company synthesised, tested and profiled drug candidates from the Dual Kinase series, comparing them with established therapeutics in various tests.

While initial results were promising, ValiRx has decided to return the project to Imperial College London for further development, with no additional financial commitment from ValiRx. As part of this, the current collaboration agreement has been terminated and responsibility for maintaining the intellectual property will revert to the university.

ValiRx is focused on early-stage cancer therapeutics and women's health, while accelerating the translation of innovative science into clinical development, leveraging its expertise to guide drug candidates from pre-clinical studies to market readiness.